EUVIMEDScopri EUVIMED
Crossref

Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services

Aaron J Wyble, V Rakesh Sethapati iD, Steven R Post, Haley McAloon, Nancy Green, Mayumi Nakagawa, Michele Cottler-Fox, Gina Drobena

Journal of Clinical Apheresis · 2025

DOI: 10.1002/jca.70048 ↗

At a glance

Journal article in Journal of Clinical Apheresis, 2025. Written by Aaron J Wyble and 7 co-authors. Institution: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. Major MEDLINE topics: Blood Component Removal, Hematopoietic Stem Cells, Cell- and Tissue-Based Therapy, Hematopoietic Stem Cell Transplantation. 41 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

In order to reflect patient needs given new treatment options for hematopoietic malignancies, autologous hematopoietic progenitor cell (HPC) collection goals were changed to 10 or 15 × 10 6 CD34+/kg (previously 20 × 10 6 CD34+/kg) for myeloma patients and to 5 × 10 6 CD34+/kg (previously 10 × 10 6 CD34+/kg) for lymphoma patients in March 2023. The minimum number of large volume leukapheresis (LVL) procedures required decreased from two to one. We analyzed the impact of these changes on apheresis and cell therapy laboratory (CTL) services. Data from the post‐implementation period of April through December in 2023 were compared to those from the same 9‐month periods in 2022 and 2021 as controls. The number of patients undergoing autologous HPC collection per month were examined. The numbers of LVL procedures, numbers of cryopreserved bags, and apheresis and CTL staffing hours and costs were determined retrospectively on a per patient and monthly basis. One‐way ANOVA with Tukey's multiple comparison was performed. The per patient averages for LVL procedures, cryopreserved bags, staff hours, and costs in apheresis and CTL services were decreased significantly in 2023 compared to both control periods. However, for monthly analyses, differences were significant between 2023 and 2021; but not between 2023 and 2022. No differences were seen between the two control periods. The changes in autologous HPC collection goals led to a significant decrease in LVL procedures and cryopreserved bags required per patient to meet collection goals, reducing costs and workload for apheresis and CTL.

Subjects

MeSH terms (MEDLINE)

Blood Component RemovalHematopoietic Stem CellsCell- and Tissue-Based TherapyHematopoietic Stem Cell TransplantationHumansLeukapheresisRetrospective StudiesMultiple MyelomaTransplantation, AutologousCryopreservationAntigens, CD34

Author keywords

HPCcryopreserved productslarge volume leukapheresisworkload cost savings

Substances

Antigens, CD34

Authors and institutions

  • Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

ORCID profiles: V Rakesh Sethapati

Cite

APA

Wyble, A. J., Sethapati, V. R., Post, S. R., McAloon, H., Green, N., Nakagawa, M., Cottler-Fox, M., & Drobena, G. (2025). Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70048

Vancouver

Wyble AJ, Sethapati VR, Post SR, McAloon H, Green N, Nakagawa M, et al. Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70048

BibTeX
@article{Wyble2025,
  author = {Wyble, Aaron J and Sethapati, V Rakesh and Post, Steven R and McAloon, Haley and Green, Nancy and Nakagawa, Mayumi and Cottler-Fox, Michele and Drobena, Gina},
  title = {Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services},
  journal = {Journal of Clinical Apheresis},
  year = {2025},
  doi = {10.1002/jca.70048}
}
Start for free →